29 - Preclinical Preparation and IND Planning (S2E14)

Hey everyone, welcome back to The Deep Dive.
Today we're really gonna get into the nitty gritty
of drug development. Kind of that journey a drug
takes from a promising molecule in the lab all
the way to that big IND application, that investigational
new drug application. Yeah. Exactly, kind of
that roadmap from the early eureka moments in
the lab to all those studies that you need to
convince the regulators that a drug is safe and
effective enough to actually go into humans.
We've got a lot of research and notes to dig
through, so let's dive right in. I'm particularly
interested in how this whole process kind of
scales up. You know, you start with a candidate
drug, but then what? Well, it's not as simple
as just making more of it. The jump from kind
of that laboratory scale to something that you
can use in clinical trials is huge. So it's not
just bigger beakers, then? Definitely not. It's
about planning and execution. Scaling up preclinical
research involves a whole bunch of activities,
from refining the drug synthesis process all
the way to conducting those rigorous in vitro
and in vivo studies. OK, hold on. Break that
down for me. In vitro versus in vivo, what's
the difference? Right, so in vitro studies are
those that are done in very controlled environments,
think test tubes and petri dishes, and they help
us understand a drug's basic properties, how
it interacts with its target, how stable it is,
and any potential toxicity. So it's kind of like
a... a first look at a drug's personality, and
then in vivo is where you kind of bring in the
real world complexity. Yeah, exactly. In vivo
studies involve testing the drug in living organisms,
usually animal models, and this helps us see
how it behaves in a more complex system. This
is where we get a grasp of how the drug is absorbed,
distributed, metabolized, and eliminated all
that ADME stuff. Got it. So you're building that
comprehensive understanding of the drug's actions
before you even think about humans, but how do
you even begin to scale up something? that started
in a tiny vial in the lab. Right. Well, that's
where pilot batch manufacturing comes in. It's
kind of a crucial bridge between the lab scale
synthesis and large -scale production. It's like
a dress rehearsal for the real manufacturing
process. OK. So you're making a small batch of
the drug, but using methods that are closer to
what a pharmaceutical company would use. Exactly.
Pilot batches help us optimize those manufacturing
processes, test different formulations, and get
enough material for those preclinical and early
clinical studies. And this is actually a great
example of how how regulatory strategy kind of
influences preclinical planning. Oh, tell me
more about that. I'm guessing the FDA has a lot
to say about how these drugs are made, even in
these early stages. Absolutely. Understanding
the regulatory guidelines is key. For example,
the FDA requires very detailed information about
the manufacturing process, the quality control
measures, and the stability data. So researchers
are always checking their work against the regulatory
rulebook. That's got to be a delicate balancing
act. Yeah. It is you need to push the boundaries
of innovation while staying within that regulatory
framework. And all that meticulous planning and
documentation is crucial for eventually filing
that IND, that investigational new drug application.
Speaking of the IND, from what I understand,
it's that big document that gets submitted to
the FDA, right? What exactly goes into that massive
file? It's a pretty comprehensive package. It
tells the story of the drug's pre -clinical journey.
It includes details about the drug's chemistry,
how it's manufactured data from all those non
-clinical pharmacology and toxicology studies,
and the proposed plan for clinical trials. Wow.
It's like compiling all the research and data
and plans into one single narrative, no pressure.
Right. It is a huge undertaking. And a key part
of that story is demonstrating that you've thoroughly
assessed the drug's safety profile. Right. it's
all about ensuring patient safety. So let's talk
more about how researchers identify and mitigate
potential risks during this preclinical phase.
One term I keep coming across is reactive metabolites.
Those sound kind of concerning. They can be.
Reactive metabolites are byproducts of drug metabolism
that can sometimes cause adverse reactions. It's
not just about how quickly a drug is cleared
from the body, but also what it leaves behind.
Okay, now that does sound concerning. What kind
of trouble can these reactive metabolites cause?
Well, they can trigger a whole range of issues
from damaging the liver to interfering with DNA
or even prompting the immune system to attack
healthy cells. That's a whole cascade of potential
problems. So how do researchers even begin to
predict and manage these risks, especially early
on? It's a multi -pronged approach. One key strategy
is early assessment of the drug's potential to
form these reactive metabolites. This often involves
using really sophisticated analytical techniques
like mass spectrometry to identify and characterize
those byproducts. Mass spectrometry, that sounds
pretty high tech. Paint me a picture, how does
that work? It's like a molecular fingerprint
scanner. Imagine you've got this mixture of molecules
and you want to know exactly what's in there
and how much of each one is present. Mass spectrometry
helps us separate and identify those molecules
based on their mass and charge. And that gives
us a detailed picture of the drug and its metabolites.
It's like having a molecular detective on the
case, breaking down the clues and revealing the
hidden dangers. But it's not just about identifying
those risky metabolites, right? You also have
to figure out how to manage them. Absolutely.
Sometimes it's about tweaking the drug structure,
optimizing its formulation, or even exploring
different routes of administration to minimize
the formation of those problematic byproducts.
So it's a constant process of refining and optimizing.
But tell me, isn't there a risk that all this
focus on safety and regulation stifles innovation?
How do researchers find that balance between
being cautious and pushing the boundaries? That's
a great question, one that's really at the heart
of drug development. It really is a constant
challenge finding that balance between innovation
and making sure everything is safe and rigorous.
On the one hand, you want to explore new things,
develop those groundbreaking treatments. But
on the other hand, you have that responsibility
to ensure patient safety, to really carefully
assess and mitigate the potential risks. So it's
not just about making a drug that works. It's
about making one that works safely. Exactly.
And that's where things get really interesting.
It's a very dynamic process, a constant back
and forth between discovery and validation. Researchers
are always looking for ways to improve that process,
to make it more efficient, more predictive, and
ultimately more patient -centered. That makes
me think of something I was reading about, the
use of AI in drug development. It feels like
AI has the potential to really change things
up. AI is definitely a game changer. We're already
seeing its impact in various stages from early
drug discovery to preclinical testing, even clinical
trial design. Okay, I'm all ears. Tell me more
about how AI is being used in these early stages.
Well, one of the most exciting areas is in predicting
potential drug toxicity. AI algorithms can look
at huge amounts of data on chemical structures,
metabolic pathways, and toxicity profiles. And
it can flag those potential red flags really
early on. It's like having a super -powered research
assistant that can go through mountains of information
and spot those problems before they even show
up. So it's like catching those reactive metabolites
we talked about earlier. But even before a drug
is even made, they could save so much time and
resources. Exactly. researchers focus on the
most promising candidates, the ones with the
best chance of success and the lowest risk of
causing any harm. That makes a lot of sense.
But I have to ask, isn't there a risk of becoming
too reliant on these algorithms? They're only
as good as the data they're trained on, right?
That's a very valid point. AI is a powerful tool,
but it's not magic. Human expertise is still
absolutely essential. It's about using AI to
enhance our understanding, to identify patterns
and generate hypotheses that we might not have
considered otherwise. So it's a partnership,
AI and human intelligence working together to
make that drug development process better. Precisely.
And that partnership goes beyond just predicting
toxicity. AI is also being used to optimize drug
formulations, to design better pre -cornicle
studies, and even to streamline the regulatory
review process. Okay, let's talk about the regulatory
side of things. How is AI impacting the way the
FDA reviews these IND applications? It's still
early days, but the potential is huge. Imagine
being able to automate the analysis of those
massive regulatory dossiers we talked about.
AI could help ensure completeness flag any inconsistencies
and even highlight areas that need more clarification.
That would free up regulatory reviewers to focus
on the more complex scientific and ethical considerations.
So it sounds like AI could make the whole process
more efficient and more transparent, which would
benefit everyone, especially those patients who
are waiting for new treatments. Exactly. It's
about using technology to streamline the process
without compromising on safety or rigor. This
has all been incredibly fascinating, but let's
zoom out for a second and think about the bigger
picture We've talked about scaling up research
navigating the regulatory landscape and embracing
new technologies But but at the end of the day,
what's the the ultimate goal of all this effort?
It's all about getting those safe and effective
treatments to the patients who need them every
step in the process from those eureka moments
in the lab to planning those clinical trials
is driven by that desire to improve human health
and well -being. That's what makes this whole
field so inspiring. It's this constant drive
to innovate, to overcome challenges, and ultimately
to make a difference in people's lives. You've
hit the nail on the head, and that brings us
to a really crucial point, the importance of
patient engagement in the drug development process.
It's not enough to just develop new drugs. We
need to make sure they actually meet the needs
of the people they're intended to help. That
makes perfect sense. How are researchers working
to bring those patient perspectives into this
complex process? One key strategy is involving
patients in the... the design of clinical trials
by getting their input on things like study endpoints
outcome measures, even the overall trial design.
You know, we can ensure that the research questions
we're asking are relevant to patients' lived
experiences. So it's about shifting from a we
-know -best approach to a more collaborative
one where patients are seen as partners in the
research process. Exactly. It's about recognizing
that patients are the ultimate experts in their
own health and that their perspectives are so
valuable in shaping the future of drug development.
That's a powerful idea and one that seems to
be gaining traction in the field. But let's not
forget that that journey from the lab bench to
the patient's bedside is long and complex. What
are some of the biggest challenges facing researchers
today as they navigate this intricate process?
Oh, there are certainly many hurdles to overcome.
One of the biggest challenges is the sheer complexity
of biological systems. Right. You can't just
test a drug and petri dish and assume it'll act
the same way in a human. Exactly. And that's
why preclinical testing is so crucial. We need
good models that can accurately predict how a
drug will behave in humans. But even the most
sophisticated models have limitations. So it's
about finding that balance between innovation
and caution, pushing the boundaries while always
keeping patient safety in mind. Absolutely. And
that takes a deep understanding of the science,
a keen awareness of the regulatory landscape,
and a real commitment to patient -centered research.
It's a tall order, but it sounds incredibly rewarding.
Yeah. And as we wrap up this part of our deep
dive, I'm curious. What are some of the emerging
trends that you think will shape the future of
drug development? What should we be keeping our
eyes on? Well, one trend that I find particularly
exciting is the rise of precision medicine, the
idea of tailoring treatments to an individual's
unique genetic makeup and lifestyle. Yeah, precision
medicine. That's the idea of kind of moving away
from that one size fits all approach to treatment,
right? Sounds calling science fiction, but also
incredibly promising. It is. It's definitely
a paradigm shift. Imagine a world where treatments
are tailoring. to your specific genetic profile,
your lifestyle, even your environmental exposures.
It's about maximizing how well the treatment
works and minimizing those side effects, truly
personalized medicine. That's incredible. But
I imagine it also raises some pretty complex
questions. How do you even begin to collect and
analyze that much individual data? And what about
the ethical implications? Access, privacy, those
are all. big things to consider. You're absolutely
right. Precision medicine relies a lot on big
data and advanced analytics. We're talking about
looking at vast amounts of genomic information,
clinical records, even lifestyle data from things
like wearable devices. It's a huge task, but
the potential benefits are enormous. It's not
just about developing new drugs. It's about understanding
how those drugs interact with an individual's
unique biology. It's like taking drug development
to a whole new level. Exactly. And that's what's
so exciting. We're starting to see things like
targeted therapies, drugs designed to work on
very specific genetic subtypes of diseases. This
is especially promising in areas like cancer
treatment, where we're moving away from those
broad chemotherapy approaches and going for more
precise and less toxic options. That's amazing.
So instead of attacking all rapidly dividing
cells, you're going after the specific mutations
that are driving the cancer. That's going to
be a huge change for patients. We're also seeing
progress in using precision medicine to predict
how someone will respond to a drug, imagine being
able to know in advance if a particular drug
is likely to work for you, or if you're at risk
for certain side effects. That would completely
change the way we prescribe and use medications,
it would make the whole process so much more
efficient and less trial and error. Exactly.
But as you mentioned earlier, there are some
really big ethical and logistical challenges
to overcome. Data privacy, access to these advanced
technologies, and making sure everyone has equal
access to these personalized treatments are all
crucial things to think about. It sounds like
precision medicine is a powerful tool, but the
one that needs to be used very responsibly. It's
not just about the science. It's about how it
affects society as a whole. Well said. It's a
multi -faceted issue that requires a lot of careful
thought and open discussion between scientists,
ethicists, policymakers, and the public. This
has been an amazing journey we've covered so
much, from the details of scaling up preclinical
research to the incredible potential of AI and
precision medicine. It's clear that drug development
is such a complex and ever -changing field. It
certainly is, but it's also a field that's driven
by this deep sense of purpose, the desire to
alleviate suffering and improve people's lives.
And it's been an absolute pleasure to dive into.
these topics with you today. I always learn so
much from our deep dives. The pleasure is all
mine. It's great to see your enthusiasm and curiosity.
And to all our listeners out there, thank you
so much for joining us on this deep dive. We
hope you've gained some new insights into the
amazing world of drug development and all the
incredible innovations that are shaping the future
of medicine. Until next time, keep those brains
engaged and those questions coming.